Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izokibep - Affibody

Next Previous
Drug Profile

Izokibep - Affibody

Alternative Names: ABY 035; ABY-035/AFO2; AFB-035; IMG-020; IMG-20

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody
  • Developer ACELYRIN; Affibody; Alumis
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Uveitis
  • Phase II Ankylosing spondylitis; Axial spondyloarthritis; Plaque psoriasis
  • Phase I/II Psoriasis
  • Discontinued Hidradenitis suppurativa; Psoriatic arthritis

Most Recent Events

  • 21 May 2025 ACELYRIN has merged with Alumis to form Alumis
  • 21 Feb 2025 ACELYRIN terminates a phase-II/III clinical trials in Uveitis (Treatment-resistant) in Austria, Spain, France, Czech Republic, USA, Germany Italy (SC) as primary and secondary endpoints did not achieve statistical significance (NCT05384249)
  • 10 Dec 2024 Adverse events and efficacy data from a phase IIB/III trial in Uveitis released by ACELYRIN

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top